In Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, a disease in which about 40% of patients have mutations in the CXCR4 gene, preliminary results with non-invasive PET imaging using [68Ga]Pentixafor have demonstrated promising results in both staging and therapy response assessment. This evidence concerns the gene CXCR4 and lymphoplasmacytic lymphoma.